

**8 August 2024**

**OptiBiotix Health plc  
("OptiBiotix" or the "Company" or the "Group")**

**Result of AGM**

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care announces that at the AGM held earlier today, all resolutions were duly passed.

The full voting results will be available on the website in due course here: <https://www.optibiotix-ir.com/content/investors/>

**For further information, please contact:**

**OptiBiotix Health plc**

Neil Davidson, Chairman  
Stephen O'Hara, Chief Executive

[www.optibiotix.com](http://www.optibiotix.com)

*Contact via Walbrook below*

**Cairn Financial Advisers LLP (NOMAD)**

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

**Peterhouse Capital Limited (Broker)**

Duncan Vasey / Lucy Williams

Tel: 020 7220 9797

**Walbrook PR Ltd**

Anna Dunphy

Mob: 07876 741 001

**About OptiBiotix - [www.optibiotix.com](http://www.optibiotix.com)**

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGPPMBTMTTMBPI